From 3 to 5 November 2025, Vienna played host to the flagship European life‑science partnering event, BIO‑Europe, bringing together thousands of biotech, pharma and investment professionals from more than 60 countries. Amid this bustling international scene, Belgium’s life‑sciences community stood out for its strong representation and proactive presence.
Strong Belgian Footing
Belgium’s life‑sciences sector has long punched above its weight—despite the country’s compact size it boasts more than 300 biotech companies and a rich ecosystem of research parks, incubators and academic institutions. For BIO‑Europe 2025, the coordination between national and regional export & investment agencies ensured Belgium’s voice was heard: the regional development agencies such as AWEX (Wallonia) and BioWin (Flanders) joined forces to share a dedicated Belgian booth at the event.
The joint Belgian stand offered a visible meeting‑place for Belgian delegates, partners and prospects — creating a home base amid the many international exhibitors. The Belgian presence extended across different company types: from mature CDMOs to early‑stage biotech innovators. Belgian‑based Ardena publicised its presence, underscoring the company’s global ambitions from a Belgian base. Regional agencies also facilitated participation (e.g., registration discounts) for Walloon companies via AWEX.
A Hub for Networking and Partnering Opportunities
The key value of BIO‑Europe lies in the structured one‑to‑one partnering meetings and networking formats — and Belgium made the most of it. Belgian participants benefited from the high visibility of the national booth and from the exposure to potential partners in therapeutics, platform technologies, CDMO services and investment.
Why Belgium Stands Out
Belgium offers several competitive advantages in the life‑sciences domain:
• A highly skilled workforce and dense R&D infrastructure
• A strategic European location with strong logistics
• A supportive regulatory, fiscal and innovation environment
For international investors or partners meeting Belgian delegates in Vienna, the message was clear: Belgium is open, experienced and globally oriented.
Key Takeaways for Fininfo Readers
• Belgium remains active, visible and internationally engaged in life sciences.
• BIO‑Europe provides crucial windows for Belgian companies to accelerate partnering and visibility.
• Belgium offers a unique concentration of services and innovation for global partners.
Looking Ahead
As the event closes in Vienna, Belgian delegates will now nurture the discussions initiated during the conference. The coming months will show which of these high‑level interactions develop into concrete partnerships, funding rounds or licensing deals. Belgium remains well‑positioned to keep its strong presence on the European life‑sciences stage.
